Mary E. Godwin sold $100k of NAUT
Senior VP, Operations at Nautilus Biotechnology, Inc.. 35,000 shares at an average of $2.85, traded Sep 17, 2024, filed Sep 18, 2024.
Score components
- +15RoleOfficer
- +10Trade size$100k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.8%, 3m -36.9%, 6m -66.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001808805-24-000065, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 17, 2024 | MOption exercise Common Stock | +35,000 | $0.46 | $16k | 35,000 | Sep 18, 2024 |
| Sep 17, 2024 | SOpen-market sale Common Stock | -35,000 | $2.85 | $100k | 0 | Sep 18, 2024 |
| Sep 17, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -35,000 | $0.00 | $0 | 400,368 | Sep 18, 2024 |
Related signals
Other insiders at Nautilus Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | NAUTsell Nautilus Biotechnology, Inc. | AH Equity Partners Bio II, L.L.C. owner | $12M 5,000,000 shares | -31% | |
| 28Weak | NAUTbuy Nautilus Biotechnology, Inc. | Sujal M Patel CEO, President, and Secretary | $65k 25,000 shares | +0% | |
| 23Weak | NAUTbuy Nautilus Biotechnology, Inc. | Kentaro Suzuki Chief Marketing Officer | $5,960 4,000 shares | - | |
| 44Moderate | Nautilus Biotechnology, Inc. | Sujal M Patel CEO, President, and Secretary | $136k 200,000 shares | +2% | |
| 29Weak | Nautilus Biotechnology, Inc. | Matthew B. Murphy General Counsel | $13k 20,000 shares | +37% | |
| 28Weak | NAUTbuy Nautilus Biotechnology, Inc. | Anna Mowry CFO and Treasurer | $11k 15,000 shares | +22% | |
| 10Weak | NAUTbuy Nautilus Biotechnology, Inc. | Parag Mallick Chief Scientist | $9,885 13,500 shares | +0% | |
| 31Weak | NAUTsell Nautilus Biotechnology, Inc. | Mary E. Godwin Senior VP, Operations | $135k 47,031 shares | -100% | |
| 39Weak | NAUTbuy Nautilus Biotechnology, Inc. | Sujal M Patel CEO, President, and Secretary | $41k 14,474 shares | +0% | |
| 38Weak | NAUTbuy Nautilus Biotechnology, Inc. | Sujal M Patel CEO, President, and Secretary | $99k 35,526 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.